Safety and Immunogenicity of Vaccination

Dear Colleagues,

Vaccination remains one of the most transformative public health interventions. However, the increasing diversity of vaccine platforms, from mRNA and viral-vectored to protein subunit and inactivated vaccines, necessitates continuous evaluation of safety and immunogenicity profiles across populations, including vulnerable subgroups. This Special Issue aims to collate cutting-edge research, clinical trial outcomes, and mechanistic insights into vaccine-induced immune responses. The issue will serve to guide those working to ensure the safety and effectiveness of vaccines, especially in the context of vaccine preparedness. We welcome original articles, systematic reviews, and short communications that address:

• Preclinical and clinical safety profiles of emerging vaccine candidates;
• Kinetics and quality of immune responses (e.g., durability, breadth, avidity);
• Correlates of protection across different vaccine platforms;
• Comparative immunogenicity across age groups, immunocompromised individuals, and special populations;
• Biomarkers for vaccine efficacy and adverse events;
• Innovations in vaccine formulation, delivery, and adjuvant systems.

This issue will serve as a reference point for scientists, regulators, and policymakers working to ensure the safety and effectiveness of next-generation vaccines, particularly in the context of pandemic preparedness and global equity.

Dr. Jennifer Serwanga
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.